Maackiain Reduces Neuroinflammation by Modulating Inflammatory Signals in LPS-Induced In Vitro and In Vivo Models

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Neuroinflammation is implicated in various neurological diseases like Alzheimer's and Parkinson's.
• Maackiain (MAA) has known anti-inflammatory properties, but its role in neuroinflammation is unclear.

Purpose of the Study:

• To investigate the therapeutic potential of Maackiain (MAA) in mitigating lipopolysaccharide (LPS)-induced neuroinflammation.
• To elucidate the underlying mechanisms of MAA's neuroprotective effects.

Main Methods:

• In vitro studies on BV2 cells to assess cell viability, nitric oxide (NO), reactive oxygen species (ROS), ferrous ion (Fe2+), and lipid peroxide accumulation.
• In vivo studies using a mouse model of LPS-induced neuroinflammation, including behavioral tests (Morris water maze) and histological analyses (Nissl staining).

Main Results:

• MAA treatment improved BV2 cell viability and reduced inflammatory markers (NO, ROS, Fe2+, lipid peroxides) in vitro.
• MAA administration in vivo enhanced memory performance and increased neuronal survival in the hippocampus and cortex.
• MAA significantly decreased the expression of inflammatory markers IBA-1, COX-2, and IL-6 in the brain.

Conclusions:

• Maackiain (MAA) demonstrates significant inhibitory effects against LPS-induced neuroinflammation.
• MAA shows potential as a therapeutic agent for treating neuroinflammatory conditions and associated neurological disorders.